Literature DB >> 8892971

Mechanism of telomerase induction during T cell activation.

A G Bodnar1, N W Kim, R B Effros, C P Chiu.   

Abstract

The progressive shortening of the ends of chromosomes (telomeres) during cell division may serve as a mitotic clock for replicative senescence. Telomerase, a ribonucleoprotein which synthesizes telomeric DNA and maintains telomere length, is absent from most normal somatic cells but is expressed in immortal cells. Low levels of telomerase activity have been detected in peripheral blood mononuclear cells (PBMC) and hematopoietic cells and an increase in telomerase activity during T cell activation has recently been reported. In this study, we show that the increase in telomerase activity during T cell activation was transient and did not prevent the loss of telomeres in long-term T cell cultures. Analysis of the mechanism of telomerase induction showed that the increase in telomerase activity was accompanied by an increase in the levels of hTR, the RNA component of human telomerase. Moreover, telomerase induction occurred in the presence of aphidicolin, indicating that DNA synthesis was not required. Increased telomerase expression was observed when PBMC were activated with phorbol myristate acetate (PMA) and ionomycin, indicating that it was independent of early transmembrane signals. It was, however, linked to the T cell signal transduction pathway, as inhibiting protein kinase C with bisindolylmaleimide prevented the increase in telomerase activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8892971     DOI: 10.1006/excr.1996.0299

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  51 in total

1.  TIN2, a new regulator of telomere length in human cells.

Authors:  S H Kim; P Kaminker; J Campisi
Journal:  Nat Genet       Date:  1999-12       Impact factor: 38.330

2.  Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.

Authors:  R V Lord; D Salonga; K D Danenberg; J H Peters; T R DeMeester; J M Park; J Johansson; K A Skinner; P Chandrasoma; S R DeMeester; C G Bremner; P I Tsai; P V Danenberg
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

Review 3.  Natural and pharmacological regulation of telomerase.

Authors:  Jean-Louis Mergny; Jean-François Riou; Patrick Mailliet; Marie-Paule Teulade-Fichou; Eric Gilson
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

Review 4.  Complex regulation of telomerase activity: implications for cancer therapy.

Authors:  K S Elenitoba-Johnson
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

Review 5.  How long should telomeres be?

Authors:  A Aviv; C B Harley
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

6.  Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes.

Authors:  K Liu; M M Schoonmaker; B L Levine; C H June; R J Hodes; N P Weng
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 7.  The role of telomerase expression and telomere length maintenance in human and mouse.

Authors:  N P Weng; R J Hodes
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

8.  Telomerase expression in uveal melanoma.

Authors:  B Heine; S E Coupland; S Kneiff; G Demel; N Bornfeld; M Hummel; H Stein
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

Review 9.  The peripheral generation of CD4+ CD25+ regulatory T cells.

Authors:  Arne N Akbar; Leonie S Taams; Mike Salmon; Milica Vukmanovic-Stejic
Journal:  Immunology       Date:  2003-07       Impact factor: 7.397

10.  Telomere loss, senescence, and genetic instability in CD4+ T lymphocytes overexpressing hTERT.

Authors:  Alexander Röth; Gabriela M Baerlocher; Mike Schertzer; Elizabeth Chavez; Ulrich Dührsen; Peter M Lansdorp
Journal:  Blood       Date:  2005-03-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.